Fact based stock research
Fresenius Medical Care (XTRA:FME)
DE0005785802
How to read the free ranks
For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. The higher the rank, the better the stock performs than its peers. And, we do this for six investment strategies:
Value - shows how good of a value the stock is. Green is "inexpensive"; red is "expensive".
Growth - shows a company's growth potential. Green is "high growth" expected; red is "tough times ahead".
Safety - relates to the amount of debt a company has. Green is low debt level; red is high debt level.
Combined Financial - this isn't an average of the first three ranks but rather a consolidated view across several financial indicators. Green = good; red = tread carefully.
(NEW) Sentiment - quantifies professional analyst ratings and holdings as well as market pulse. Green = positive sentiment; red = skepticism (Only available to Premium Subscribers).
(NEW) 360° View - the ultimate rating with all financial and non-financial indicators.
Fresenius Medical Care stock research in summary
ANALYSIS: With an Obermatt Combined Rank of 91 (better than 91% compared with investment alternatives), Fresenius Medical Care (Health Care Services, Germany) shares have much better financial characteristics than comparable stocks. Shares of Fresenius Medical Care are a good value (attractively priced) with a consolidated Value Rank of 95 (better than 95% of alternatives), show above-average growth (Growth Rank of 56), and are safely financed (Safety Rank of 59), which means low debt burdens. ...read more
RECOMMENDATION: A Combined Rank of 91, is a strong buy recommendation based on Fresenius Medical Care's financial characteristics. As the company Fresenius Medical Care's key financial metrics all exhibit excellent performance, such as good value (Obermatt Value Rank of 95), above-average growth (Obermatt Growth Rank of 56), and indicate that the company is safely financed (Obermatt Safety Rank of 59), it is a solid stock investment where the risk of paying too much for the share is limited, unless the company has a bleak future. Such good financial performance can indicate that the company's future might actually be challenging, as it may be difficult to maintain the good performance. If they are safely financed and have been growing above average, and are still a good value, it means that the market is keeping prices low, for a reason which may become clearer over time. We recommend evaluating the future of Fresenius Medical Care. If you believe the company's future is market-typical or even better, this could be an argument for a share purchase. Obermatt Premium subscribers can further check the stock’s Sentiment Ranks, which also flow into the Obermatt 360° View for investors. ...read more
Latest Obermatt Ranks
Log in or sign up to see the new 360° View and Sentiment ranks.
360° Viewnew| Country | Germany |
| Industry | Health Care Services |
| Index | CDAX, DAX 40, Dividends Europe, Human Rights |
| Size class | XX-Large |
This stock has achievements: Top 10 Stock.
27-Mar-2025. Stock data may be delayed. Log in or sign up to get the most recent research.
Analysts rarely agree on a stock’s future. So, who do you believe? Obermatt translates those collective views into a single Sentiment Rank. That plus the financial ranks give you the ultimate 360° View. Sign up to access them.
It’s easier said than done. When your stock drops, it’s easy to want to sell it and find a better performer. Think twice, or even three times, before trading. Those fees (especially the hidden ones) can eat up your gains.
Review the performance ranks of the individual metrics that form each investment strategy.
Research History: Fresenius Medical Care
| RESEARCH HISTORY | 2022 | 2023 | 2024 | 2025 | ||||
|---|---|---|---|---|---|---|---|---|
| VALUE | ||||||||
| VALUE | 89 |
|
83 |
|
88 |
|
95 |
|
| GROWTH | ||||||||
| GROWTH | 27 |
|
31 |
|
38 |
|
56 |
|
| SAFETY | ||||||||
| SAFETY | 41 |
|
74 |
|
61 |
|
59 |
|
| SENTIMENT | ||||||||
| SENTIMENT | 9 |
|
23 |
|
58 |
|
new |
|
| 360° VIEW | ||||||||
| 360° VIEW | 31 |
|
54 |
|
81 |
|
new |
|
Combined financial peformance in Detail
ANALYSIS: With an Obermatt Combined Rank of 91 (better than 91% compared with investment alternatives), Fresenius Medical Care (Health Care Services, Germany) shares have much better financial characteristics than comparable stocks. Shares of Fresenius Medical Care are a good value (attractively priced) with a consolidated Value Rank of 95 (better than 95% of alternatives), show above-average growth (Growth Rank of 56), and are safely financed (Safety Rank of 59), which means low debt burdens. ...read more
RECOMMENDATION: A Combined Rank of 91, is a strong buy recommendation based on Fresenius Medical Care's financial characteristics. As the company Fresenius Medical Care's key financial metrics all exhibit excellent performance, such as good value (Obermatt Value Rank of 95), above-average growth (Obermatt Growth Rank of 56), and indicate that the company is safely financed (Obermatt Safety Rank of 59), it is a solid stock investment where the risk of paying too much for the share is limited, unless the company has a bleak future. Such good financial performance can indicate that the company's future might actually be challenging, as it may be difficult to maintain the good performance. If they are safely financed and have been growing above average, and are still a good value, it means that the market is keeping prices low, for a reason which may become clearer over time. We recommend evaluating the future of Fresenius Medical Care. If you believe the company's future is market-typical or even better, this could be an argument for a share purchase. Obermatt Premium subscribers can further check the stock’s Sentiment Ranks, which also flow into the Obermatt 360° View for investors. ...read more
| RESEARCH HISTORY | 2022 | 2023 | 2024 | 2025 | ||||
|---|---|---|---|---|---|---|---|---|
| VALUE | ||||||||
| VALUE | 89 |
|
83 |
|
88 |
|
95 |
|
| GROWTH | ||||||||
| GROWTH | 27 |
|
31 |
|
38 |
|
56 |
|
| SAFETY | ||||||||
| SAFETY | 41 |
|
74 |
|
61 |
|
59 |
|
| COMBINED | ||||||||
| COMBINED | 61 |
|
82 |
|
83 |
|
91 |
|
Value Metrics in Detail
ANALYSIS: With an Obermatt Value Rank of 95 (better than 95% compared with alternatives) for 2025, Fresenius Medical Care shares are significantly less expensive than comparable stocks. The Value Rank is based on consolidating four value indicators that are all above average for Fresenius Medical Care. Price-to-Sales is 72 which means that the stock price compared with what market professionals expect for future sales is lower than for 72% of comparable companies, indicating a good value for Fresenius Medical Care's revenue size. The same is valid for expected Price-to-Profits, more favorable than for 83% of alternatives, and this is also true for the Price-to-Book capital ratio (also referred to as market-to-book ratio) with a Price-to-Capital Rank of 85. Compared with other companies in the same industry, dividend yields of Fresenius Medical Care are expected to be higher than for 88% of all competitors (a Dividend Yield rank of 88). ...read more
RECOMMENDATION: The overall picture with a consolidated Value Rank of 95, is a buy recommendation based on Fresenius Medical Care's stock price compared with the company's operational size and dividend yields. Since all value metrics are above the industry average, there is no objection to investing in Fresenius Medical Care based on its detailed value metrics. We recommend further analyzing the stock with Obermatt’s Value, Safety, and Sentiment Ranks, including the 360° View, before making an investment decision. ...read more
| VALUE METRICS | 2022 | 2023 | 2024 | 2025 | ||||
|---|---|---|---|---|---|---|---|---|
| PRICE VS. REVENUES (P/S) | ||||||||
| PRICE VS. REVENUES (P/S) | 75 |
|
72 |
|
69 |
|
72 |
|
| PRICE VS. PROFITS (P/E) | ||||||||
| PRICE VS. PROFITS (P/E) | 89 |
|
77 |
|
77 |
|
83 |
|
| PRICE VS. CAPITAL (Market-to-Book) | ||||||||
| PRICE VS. CAPITAL (Market-to-Book) | 84 |
|
84 |
|
82 |
|
85 |
|
| DIVIDEND YIELD | ||||||||
| DIVIDEND YIELD | 84 |
|
74 |
|
77 |
|
88 |
|
| CONSOLIDATED RANK: VALUE | ||||||||
| CONSOLIDATED RANK: VALUE | 89 |
|
83 |
|
88 |
|
95 |
|
Growth Metrics in Detail
ANALYSIS: With an Obermatt Growth Rank of 56 (better than 56% compared with alternatives), Fresenius Medical Care shows an above-average growth dynamic in its industry. Investors also speak of positive momentum. The Growth Rank is based on consolidating four value indicators, with all but one indicator above average for Fresenius Medical Care. Profit Growth has a rank of 60 which means that currently professionals expect the company to grow its profits more than 60% of its competitors. The same is valid for capital growth and stock returns. Capital Growth has a rank of 68, and Stock Returns has a rank of 85 which means that the stock returns have recently been above 85% of alternative investments. Only revenue growth is low with a Sales Growth has a rank of 15 (85% of its competitors are better). ...read more
RECOMMENDATION: The overall picture with a consolidated Growth Rank of 56, is a buy recommendation for growth and momentum investors. The many positive growth indicators indicate a positive growth momentum with only low revenue growth. That can also be attributed to divestments or the sale of unprofitable businesses. If that is the reason, overall growth is well on track to making this stock attractive for growth investors. While momentum is a popular investment factor, the value aspect might be the more important one, in the longer term. We recommend analyzing the stock with Obermatt’s Value, Safety, and Sentiment Ranks to arrive at a 360° View of the stock purchase case. ...read more
| GROWTH METRICS | 2022 | 2023 | 2024 | 2025 | ||||
|---|---|---|---|---|---|---|---|---|
| REVENUE GROWTH | ||||||||
| REVENUE GROWTH | 32 |
|
10 |
|
29 |
|
15 |
|
| PROFIT GROWTH | ||||||||
| PROFIT GROWTH | 6 |
|
8 |
|
39 |
|
60 |
|
| CAPITAL GROWTH | ||||||||
| CAPITAL GROWTH | 84 |
|
82 |
|
42 |
|
68 |
|
| STOCK RETURNS | ||||||||
| STOCK RETURNS | 27 |
|
83 |
|
82 |
|
85 |
|
| CONSOLIDATED RANK: GROWTH | ||||||||
| CONSOLIDATED RANK: GROWTH | 27 |
|
31 |
|
38 |
|
56 |
|
Safety Metrics in Detail
ANALYSIS: With an Obermatt Safety Rank of 59 (better than 59% compared with alternatives), the company Fresenius Medical Care has financing practices on the safer side, which mean that their overall debt burden is lower than average. This doesn't mean that the business of Fresenius Medical Care is safe, it only means that the company is on the safer side regarding possible bankruptcy, assuming that public reporting is correct. The Safety Rank is based on consolidating three financing indicators, with just one indicator above average for Fresenius Medical Care and the other two below average. Refinancing is at 71, meaning the portion of the debt about to be refinanced is below average. It has less debt in the refinancing stage than 71% of its competitors. But Leverage is high with a rank of 40, meaning the company has an above-average debt-to-equity ratio. It has more debt than 60% of its competitors. Liquidity is also on the riskier side with a rank of 32, meaning the company generates less profit to service its debt than 68% of its competitors. ...read more
RECOMMENDATION: With a consolidated Safety Rank of 59 (better than 59% compared with alternatives), Fresenius Medical Care has a financing structure that is safer than that of its competitors. A good Refinancing Rank means that the problems of the company may not be around the corner. But high Leverage is only good if things go well, and low Liquidity is a signal for caution. The financing signals for Fresenius Medical Care are on the riskier side, requiring the company's future to be on the safer side. Investors may want to look at Growth and Sentiment ranks before making an investment decision. In the long-term, investors may have a debt challenge with Fresenius Medical Care and should also compare Obermatt’s Value, Growth, and Sentiment Ranks before making a decision. ...read more
| SAFETY METRICS | 2022 | 2023 | 2024 | 2025 | ||||
|---|---|---|---|---|---|---|---|---|
| LEVERAGE | ||||||||
| LEVERAGE | 24 |
|
38 |
|
31 |
|
40 |
|
| REFINANCING | ||||||||
| REFINANCING | 47 |
|
77 |
|
77 |
|
71 |
|
| LIQUIDITY | ||||||||
| LIQUIDITY | 39 |
|
42 |
|
42 |
|
32 |
|
| CONSOLIDATED RANK: SAFETY | ||||||||
| CONSOLIDATED RANK: SAFETY | 41 |
|
74 |
|
61 |
|
59 |
|
Sentiment Metrics in Detail
| SENTIMENT | 2022 | 2023 | 2024 | 2025 | ||||
|---|---|---|---|---|---|---|---|---|
| ANALYST OPINIONS | ||||||||
| ANALYST OPINIONS | n/a |
|
8 |
|
13 |
|
new |
|
| OPINIONS CHANGE | ||||||||
| OPINIONS CHANGE | 29 |
|
53 |
|
65 |
|
new |
|
| PRO HOLDINGS | ||||||||
| PRO HOLDINGS | 46 |
|
24 |
|
51 |
|
new |
|
| MARKET PULSE | ||||||||
| MARKET PULSE | 34 |
|
64 |
|
81 |
|
new |
|
| CONSOLIDATED RANK: SENTIMENT | ||||||||
| CONSOLIDATED RANK: SENTIMENT | 9 |
|
23 |
|
58 |
|
new |
|
Free stock analysis by the purely fact based Obermatt Method for Fresenius Medical Care from March 27, 2025.
Obermatt Portfolio Performance
We’re so convinced about our free research, that we buy our stock tips.
See the performance of the Obermatt portfolio.